<- Go Home
Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Market Cap
$1.1B
Volume
815.8K
Cash and Equivalents
$246.0M
EBITDA
$178.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$439.6M
Profit Margin
63.25%
52 Week High
$34.01
52 Week Low
$11.16
Dividend
N/A
Price / Book Value
1.44
Price / Earnings
-11.91
Price / Tangible Book Value
3.48
Enterprise Value
$1.3B
Enterprise Value / EBITDA
6.56
Operating Income
$102.0M
Return on Equity
11.48%
Return on Assets
4.17
Cash and Short Term Investments
$453.8M
Debt
$644.4M
Equity
$749.6M
Revenue
$695.0M
Unlevered FCF
$176.0M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium